ArticleMultiple sclerosis and related disorders2020
Multiple sclerosis following SARS-CoV-2 infection.
Article in Multiple sclerosis and related disorders, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
95 citing papers in PubMed, 9 syntheses or guidelines pooled it, 175 citations in OpenAlex.
- Multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) following COVID-19 vaccines: A systematic review.Revue neurologique · 2023Pooled it
- A Systematic Review on Neurological Aspects of COVID-19: Exploring the Relationship Between COVID-19-Related Olfactory Dysfunction and Neuroinvasion.Frontiers in neurology · 2022Pooled it
- COVID-19 and the risk of CNS demyelinating diseases: A systematic review.Frontiers in neurology · 2022Pooled it
- COVID-19 associated brain/spinal cord lesions and leptomeningeal enhancement: A meta-analysis of the relationship to CSF SARS-CoV-2.Journal of neuroimaging : official journal of the American Society of Neuroimaging · 2021Pooled it
- Cerebrospinal fluid from COVID-19 patients with olfactory/gustatory dysfunction: A review.Clinical neurology and neurosurgery · 2021Pooled it
- Coronavirus disease 2019 and neurodegenerative disease: what will the future bring?Current opinion in psychiatry · 2021Pooled it
- Cerebrospinal fluid in COVID-19: A systematic review of the literature.Journal of the neurological sciences · 2021Pooled it
- Pooled it
- Autoimmune and Rheumatic Manifestations Associated With COVID-19 in Adults: An Updated Systematic Review.Frontiers in immunologyPooled it
- Spinal fluid antibody profile against bacteria demonstrates intrathecal antibody production in demyelinating diseases.Journal of molecular medicine (Berlin, Germany) · 2026Article
- NETosis: A key player in autoimmunity, COVID-19, and long COVID.Journal of translational autoimmunity · 2025Review
- The age-dependent neuroglial interaction with peripheral immune cells in coronavirus-induced neuroinflammation with a special emphasis on COVID-19.Biogerontology · 2025Review
- Article
- The impact of social and environmental factors on triggering multiple sclerosis onset, before and during the COVID-19 pandemic: a retrospective study from Iran.BMC neurology · 2024Article
- Understanding autoimmune response after SARS-CoV-2 infection and the pathogenesis/mechanisms of long COVID.Medical review (2021) · 2024Review
- Ocular Implications of COVID-19 Infection and Vaccine-Related Adverse Events.Journal of personalized medicine · 2024Review
- Multiple Sclerosis Onset before and after COVID-19 Vaccination: Can HLA Haplotype Be Determinant?International journal of molecular sciences · 2024Article
- Visual evoked potential abnormalities in patients with COVID-19.Revista da Associacao Medica Brasileira (1992) · 2024Article
- Host factors of SARS-CoV-2 in infection, pathogenesis, and long-term effects.Frontiers in cellular and infection microbiology · 2024Review
- Multiple Sclerosis and COVID-19: An Overview on Risk, Severity, and Association With Disease Modifying Therapies.Neuroscience insights · 2024Review
35 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SARS-CoV-2 infection can produce neurological features. The most common are headache, anosmia and dysgeusia but patients may also develop other central nervous system (CNS) injuries. We present a patient affected by Covid-19 who initially consulted for decreased visual acuity. The MRI showed inflammation in the right optic nerve and demyelinating lesions in the CNS. We speculate that an immune mechanism induced by SARS-CoV-2, which can activate lymphocytes and an inflammatory response, plays a role in the clinical onset of the disease. This pathogen may be associated with either the triggering or the exacerbation of inflammatory/demyelinating disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.